Prognostic value of T-cells between primary colorectal cancer (pCRC) and its paired synchronous and metachronous liver metastasis (LM) is underinvestigated and is the subject of the present study. We enrolled into this retrospective cohort study patients, who underwent resection of both pCRC and synchronous LM (N = 55) or metachronous LM (N = 44). After immunohistochemical staining for CD3+, CD8+, and CD45R0+ whole slides were scanned and T-cell densities were quantified using QuPath software in tumor center (TC), inner margin (IM), outer margin (OM), and peritumor zone (PT) of pCRC and LM. High densities of CD8+ T-cells in TC, OM and PT of synchronous LM were associated with longer disease-free survival (DFS). Greater densities of CD3+ T-cells in IM and PT and CD8+ T-cells in IM, OM and PT in synchronous LM over pCRC were associated with longer DFS. Greater densities of CD8+ T-cells in the TC and IM and CD3+ T-cells in the IM of pCRC were found in the metachronous over synchronous group. The first novel finding demonstrated that high density of CD8+ T cells in synchronous LM were associated with favorable outcome. The second finding of high CD8+ cell density in pCRC in metachronous over synchronous CRC may provide a mechanistic basis for the delay of metastatic spread. Both findings could be applied clinically with own reference values.

Laboratory of Translational Cancer Genomics Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Zobrazit více v PubMed

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7‐33. PubMed

WHO/Colorectal cancer/Fact sheets. Available from: https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer.

Hong Y, Kim J, Choi YJ, Kang JG. Clinical study of colorectal cancer operation: survival analysis. Korean J Clin Oncol. 2020;16(1):3‐8. PubMed PMC

Dillekas H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 2019;8(12):5574‐5576. PubMed PMC

Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog. 2013;18(1–2):43‐73. PubMed PMC

Slesser AA, Georgiou P, Brown G, Mudan S, Goldin R, Tekkis P. The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review. Clin Exp Metastasis. 2013;30(4):457‐470. PubMed

Colloca GA, Venturino A, Guarneri D. Different variables predict the outcome of patients with synchronous versus metachronous metastases of colorectal cancer. Clin Transl Oncol. 2020;22(8):1399‐1406. PubMed

Reboux N, Jooste V, Goungounga J, Robaszkiewicz M, Nousbaum JB, Bouvier AM. Incidence and survival in synchronous and metachronous liver metastases from colorectal cancer. JAMA Netw Open. 2022;5(10):e2236666. PubMed PMC

Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: metastases to a single organ. World J Gastroenterol. 2015;21(41):11767‐11776. PubMed PMC

Laubert T, Habermann JK, Hemmelmann C, et al. Metachronous metastasis‐ and survival‐analysis show prognostic importance of lymphadenectomy for colon carcinomas. BMC Gastroenterol. 2012;12:24. PubMed PMC

Lan YT, Chang SC, Lin PC, et al. Clinicopathological and molecular features between synchronous and metachronous metastases in colorectal cancer. Am J Cancer Res. 2021;11(4):1646‐1658. PubMed PMC

Quireze Junior C, Brasil AMS, Morais LK, Campion ERL, Taveira EJF, Rassi MC. Metachronous colorectal liver metastases has better prognosis—is it true? Arq Gastroenterol. 2018;55(3):258‐263. PubMed

Benson AB, Venook AP, Al‐Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329‐359. PubMed

Jones RP, Jackson R, Dunne DF, et al. Systematic review and meta‐analysis of follow‐up after hepatectomy for colorectal liver metastases. Br J Surg. 2012;99(4):477‐486. PubMed

Chandra R, Karalis JD, Liu C, et al. The colorectal cancer tumor microenvironment and its impact on liver and lung metastasis. Cancers (Basel). 2021;13(24):6206. PubMed PMC

Cervantes A, Adam R, Rosello S, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow‐up. Ann Oncol. 2023;34(1):10‐32. PubMed

Wang Y, Lin HC, Huang MY, et al. The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases. Cancer Immunol Immunother. 2018;67(3):435‐444. PubMed PMC

Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol. 2014;232(2):199‐209. PubMed PMC

Pages F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128‐2139. PubMed

Mlecnik B, Van den Eynde M, Bindea G, et al. Comprehensive Intrametastatic immune quantification and major impact of Immunoscore on survival. J Natl Cancer Inst. 2018;110(1):97‐108. PubMed

Baldin P, Van den Eynde M, Mlecnik B, Galon J. Immunity to live: an immunopathoscore using the consensus Immunoscore to best define the risk of recurrence and death in stage IV metastatic patients. Onco Targets Ther. 2020;9(1):1826133. PubMed PMC

Shibutani M, Maeda K, Nagahara H, et al. A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study. BMC Cancer. 2018;18(1):371. PubMed PMC

Wang E, Shibutani M, Nagahara H, et al. Prognostic value of the density of tumor‐infiltrating lymphocytes in colorectal cancer liver metastases. Oncol Lett. 2021;22(6):837. PubMed PMC

Van den Eynde M, Mlecnik B, Bindea G, et al. The link between the multiverse of immune microenvironments in metastases and the survival of colorectal cancer patients. Cancer Cell. 2018;34(6):1012‐1026.e3. PubMed

Zhou SN, Pan WT, Pan MX, et al. Comparison of immune microenvironment between colon and liver metastatic tissue in colon cancer patients with liver metastasis. Dig Dis Sci. 2021;66(2):474‐482. PubMed

Halama N, Spille A, Lerchl T, et al. Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration. Onco Targets Ther. 2013;2(4):e24116. PubMed PMC

Peng J, Wang Y, Zhang R, et al. Immune cell infiltration in the microenvironment of liver oligometastasis from colorectal cancer: Intratumoural CD8/CD3 ratio is a valuable prognostic index for patients undergoing liver Metastasectomy. Cancers. 2019;11:1922. PubMed PMC

Lee WS, Kang M, Baek JH, Lee JI, Ha SY. Clinical impact of tumor‐infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis. Ann Surg Oncol. 2013;20(2):697‐702. PubMed

Adam R, de Gramont A, Figueras J, et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015;41(9):729‐741. PubMed

Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93‐99. PubMed

Ali E, Cervenkova L, Palek R, et al. Mast cells in the microenvironment of hepatocellular carcinoma confer favorable prognosis: a retrospective study using QuPath image analysis software. J Vis Exp. 2024;206. PubMed

van Pelt GW, Kjaer‐Frifeldt S, van Krieken J, et al. Scoring the tumor‐stroma ratio in colon cancer: procedure and recommendations. Virchows Arch. 2018;473(4):405‐412. PubMed PMC

finalfit: quickly create elegant regression results tables and plots when modelling. [https://github.com/ewenharrison/finalfit]

survminer: drawing survival curves using ‘ggplot2’. [https://rpkgs.datanovia.com/survminer/index.html]

A package for survival analysis in R. R package version 3.2–13. [https://CRAN.R-project.org/package=survival]

Baldin P, Van den Eynde M, Mlecnik B, et al. Prognostic assessment of resected colorectal liver metastases integrating pathological features, RAS mutation and Immunoscore. J Pathol Clin Res. 2021;7(1):27‐41. PubMed PMC

Chen DS, Mellman I. Elements of cancer immunity and the cancer‐immune set point. Nature. 2017;541(7637):321‐330. PubMed

Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity. 2020;52(1):55‐81. PubMed

Trailin A, Cervenkova L, Ambrozkiewicz F, et al. T‐ and B‐cells in the inner invasive margin of hepatocellular carcinoma after resection associate with favorable prognosis. Cancers (Basel). 2022;14(3):604. PubMed PMC

Janssen LME, Ramsay EE, Logsdon CD, Overwijk WW. The immune system in cancer metastasis: friend or foe? J Immunother Cancer. 2017;5(1):79. PubMed PMC

He Y, Han Y, Fan AH, et al. Multi‐perspective comparison of the immune microenvironment of primary colorectal cancer and liver metastases. J Transl Med. 2022;20(1):454. PubMed PMC

Jary M, Liu WW, Yan D, et al. Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study. Mol Oncol. 2022;16(11):2260‐2273. PubMed PMC

Galon J, Costes A, Sanchez‐Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960‐1964. PubMed

Kuwahara T, Hazama S, Suzuki N, et al. Intratumoural‐infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer. Br J Cancer. 2019;121(8):659‐665. PubMed PMC

Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782‐795. PubMed

Mlecnik B, Bindea G, Kirilovsky A, et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2016;8(327):327ra26. PubMed

Markowski AR, Markowska AJ, Ustymowicz W, Pryczynicz A, Guzinska‐Ustymowicz K. Simultaneous analysis of tumor‐infiltrating immune cells density, tumor budding status, and presence of lymphoid follicles in CRC tissue. Sci Rep. 2022;12(1):21732. PubMed PMC

Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74‐80. PubMed

Kim SK, Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front Pharmacol. 2022;13:868695. PubMed PMC

Di Caro G, Bergomas F, Grizzi F, et al. Occurrence of tertiary lymphoid tissue is associated with T‐cell infiltration and predicts better prognosis in early‐stage colorectal cancers. Clin Cancer Res. 2014;20(8):2147‐2158. PubMed

Colbeck EJ, Ager A, Gallimore A, Jones GW. Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease? Front Immunol. 2017;8:1830. PubMed PMC

Hendry S, Salgado R, Gevaert T, et al. Assessing tumor‐infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international Immunooncology biomarkers working group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol. 2017;24(5):235‐251. PubMed PMC